2019
DOI: 10.1007/s13300-019-00698-9
|View full text |Cite
|
Sign up to set email alerts
|

Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK

Abstract: IntroductionThe results of recently completed cardiovascular outcomes trials in patients with type 2 diabetes mellitus (T2DM) suggest that sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide (GLP) 1 receptor agonists have enhanced cardioprotective properties in patients with established cardiovascular disease (eCVD), but to a lesser degree in those without eCVD. SGLT2 inhibitors appear to be particularly beneficial in patients with heart failure. As recent data for the UK are lacking, w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

2
22
0
3

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 25 publications
(27 citation statements)
references
References 16 publications
2
22
0
3
Order By: Relevance
“…In previous studies that have used the cutoff value of ABI ≤ 0.90, the prevalence of PAD in type 2 DM was about 10.0% in patients with a mean age of 63 years in Taiwan, 10.4% in Malay patients (mean age, 63 years) who living in Singapore, and 9.5% in patients (age > 40 years) in the US [26][27][28]. According to the real-world database, PAD was reported in 18.7% of patients with type 2 DM (mean age, 65 years) in the UK and in 13.6% patients with type 2 DM (mean age, 66 years) in the US [29,30]. In the present cohort, PAD prevalence was 8.4% when ABI ≤ 0.90 was the only criterion used, but…”
Section: Discussionmentioning
confidence: 99%
“…In previous studies that have used the cutoff value of ABI ≤ 0.90, the prevalence of PAD in type 2 DM was about 10.0% in patients with a mean age of 63 years in Taiwan, 10.4% in Malay patients (mean age, 63 years) who living in Singapore, and 9.5% in patients (age > 40 years) in the US [26][27][28]. According to the real-world database, PAD was reported in 18.7% of patients with type 2 DM (mean age, 65 years) in the UK and in 13.6% patients with type 2 DM (mean age, 66 years) in the US [29,30]. In the present cohort, PAD prevalence was 8.4% when ABI ≤ 0.90 was the only criterion used, but…”
Section: Discussionmentioning
confidence: 99%
“…In Taiwan, annual screening for foot complications is recommended in the clinical guidelines and in the P4P program for patients with DM [14,51]. In previous studies that have used the cutoff value of ABI ≤ 0.90, the prevalence of PAD in type 2 DM was approximately 10.0% in patients with a mean age of 63 years in of real-world clinical diagnosis, PAD was reported in 18.7% of patients with type 2 DM (mean age, 65 years) in the UK and in 13.6% of patients with type 2 DM (mean age, 66 years) in the US [55,56]. In the present cohort, the prevalence of PAD was 8.4% when ABI ≤ 0.90 was the only criterion used, but the rate increased to 17.4% when the combination of ABI ≤ 0.90 and %MAP > 45% was used.…”
Section: Discussionmentioning
confidence: 99%
“…In previous studies that have used the cutoff value of ABI ≤ 0.90, the prevalence of PAD in type 2 DM was approximately 10.0% in patients with a mean age of 63 years in Taiwan, 10.4% in Malay patients (mean age, 63 years) who lived in Singapore, and 9.5% in patients aged > 40 years in the US [ 52 54 ]. According to database of real-world clinical diagnosis, PAD was reported in 18.7% of patients with type 2 DM (mean age, 65 years) in the UK and in 13.6% of patients with type 2 DM (mean age, 66 years) in the US [ 55 , 56 ]. In the present cohort, the prevalence of PAD was 8.4% when ABI ≤ 0.90 was the only criterion used, but the rate increased to 17.4% when the combination of ABI ≤ 0.90 and %MAP > 45% was used.…”
Section: Discussionmentioning
confidence: 99%